ABCL: Bull Flag detected on 1 Sep 2026

ABCL formed a bull flag pattern after jumping 41% on successful Phase 2 trial results for ABCL635, with the stock consolidating between support at $10.83 and resistance at $12.50. Structure score of 15.0 reflects clean flag formation, while breakout score of 10.4 and volume score of 12.0 indicate moderate momentum—current volume of 4.92M shares is just 47% of the 20-day average. Pattern quality overall: 77.4/98, with 75.13% historical win probability. Target conservative is $11.86, a modest 3.3% move above current $11.48 price.

AbCellera stock jumped 41% in early August 2026 after announcing positive Phase 2 trial results for ABCL635, a hot flash treatment candidate, raising the company's market value to nearly $3 billion. The company signed collaborations with Jazz Pharmaceuticals and Vertex Pharmaceuticals in mid-2026, adding over $100 million in upfront cash. The company ended Q2 2026 with over $675 million in total available liquidity, providing runway for clinical execution. CEO Carl Hansen stated he believes ABCL635 has blockbuster potential. The stock gained 101% over one month as these catalysts fired, creating the technical setup now consolidating.

A successful breakout above $12.50 resistance would target $11.86 conservatively (modest measured move), though the flag structure suggests potential for larger extended moves if volume increases above the 10.5M share average. Invalidation occurs below $10.83 support. With 75.13% historical win probability and RSI at 62.7 (neither overbought nor oversold), the pattern suggests upside bias if confirmed by volume expansion. Market regime is bullish (0.59 score) and healthcare sector is bullish (0.51 score), providing tailwinds for pattern resolution.

ABCL is a clinical-stage biotech with beta of 1.37, indicating elevated volatility relative to broader market. The company generated a net loss of $55.4 million in Q2 2026, and while liquidity is strong, cash burn is material. The 41% post-earnings jump was extreme; profit-taking pullbacks are typical after such violent moves, potentially invalidating the flag. Stock is only 8.74% below 52-week highs, limiting upside cushion. ATR of 0.94 (8.19% of price) signals potential for sharp reversals. Next catalyst—Phase 2 efficacy data or Phase 1 readouts—could reset the pattern entirely if disappointing.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.